Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension
Public ClinicalTrials.gov record NCT00881530. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 78 Week Open Label Extension to Trials Assessing the Safety and Efficacy of BI 10773 as Monotherapy or in Combination With Metformin in Type 2 Diabetic Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of the current study is to investigate the safety and efficacy of BI 10773 in 2 different doses compared to Metformin or to Sitagliptin given for 78 weeks in different modalities of treatment in patients with type 2 diabetes mellitus.
Study identification
- NCT ID
- NCT00881530
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 660 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2009 (Type not available)
- Primary completion
- May 2011 (Actual)
- Completion
- Not listed
- Last update posted
- Jun 16, 2014
Started 2009
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1245.24.101001 Boehringer Ingelheim Investigational Site | Mission Viejo | California | — | — |
| 1245.24.101028 Boehringer Ingelheim Investigational Site | Spring Valley | California | — | — |
| 1245.24.101027 Boehringer Ingelheim Investigational Site | Walnut Creek | California | — | — |
| 1245.24.101004 Boehringer Ingelheim Investigational Site | Clearwarter | Florida | — | — |
| 1245.24.101005 Boehringer Ingelheim Investigational Site | Miami | Florida | — | — |
| 1245.24.101024 Boehringer Ingelheim Investigational Site | Saint Cloud | Florida | — | — |
| 1245.24.101014 Boehringer Ingelheim Investigational Site | Roswell | Georgia | — | — |
| 1245.24.101016 Boehringer Ingelheim Investigational Site | Staten Island | New York | — | — |
| 1245.24.101006 Boehringer Ingelheim Investigational Site | Wadsworth | Ohio | — | — |
| 1245.24.101023 Boehringer Ingelheim Investigational Site | Norristown | Pennsylvania | — | — |
| 1245.24.101015 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 1245.24.101025 Boehringer Ingelheim Investigational Site | Federal Way | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 125 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00881530, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 16, 2014 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00881530 live on ClinicalTrials.gov.